Regeneron and Sanofi Report the US FDA Approval of Dupixent (Dupilumab) for Chronic Spontaneous Urticaria (CSU)

Why It Matters

The approval gives clinicians a targeted, biologic option for children with refractory CSU, addressing an unmet need and potentially shifting treatment algorithms away from higher‑dose antihistamines. It also broadens Sanofi‑Regeneron’s dermatology portfolio, strengthening its competitive position in the allergy‑immunology space.

Key Takeaways

• FDA approves Dupixent for children 2‑11 with chronic spontaneous urticaria
• Trials showed significant itch reduction and higher well‑controlled disease rates
• Dosing: 300 mg Q2W; <60 kg patients receive 200 mg
• Dupixent adds first biologic option for pediatric CSU after antihistamine failure
• Approval expands Sanofi‑Regeneron’s dermatology portfolio, boosting market share

Pulse Analysis

Chronic spontaneous urticaria affects millions of Americans, causing daily itching, hives, and reduced quality of life. Traditional management relies on H1 antihistamines, yet a sizable subset of patients—especially children—remain uncontrolled. Dupixent, a monoclonal antibody that blocks interleukin‑4 and interleukin‑13 signaling, has already transformed care for atopic dermatitis and asthma. Its FDA clearance for pediatric CSU marks a pivotal expansion, offering a disease‑modifying approach that directly targets the underlying immune pathways rather than merely masking symptoms.

The approval rests on robust data from the LIBERTY‑CUPID program. In two Phase III trials, Dupixent achieved statistically significant reductions in itch severity scores and urticaria activity at week 24 compared with placebo, while also increasing the proportion of patients achieving well‑controlled disease or complete remission. The CUPIDKids study confirmed safety and efficacy in children aged two to eleven, using weight‑adjusted dosing (200 mg for <60 kg, 300 mg for larger patients). Adverse events were comparable to placebo, reinforcing the drug’s favorable risk profile. These results give physicians a clear, evidence‑based option for patients who have exhausted antihistamine therapy.

From a commercial perspective, the clearance diversifies Dupixent’s indication slate and deepens Sanofi‑Regeneron’s foothold in the high‑growth dermatology and immunology markets. Competitors such as LEO Pharma’s lebrikizumab and emerging JAK inhibitors will now face a biologic with an established safety record and broad payer acceptance. The move also positions the partnership to leverage cross‑indication synergies, potentially accelerating future approvals in related allergic diseases. As insurers incorporate Dupixent into formularies for pediatric CSU, the therapy is poised to capture significant market share and drive incremental revenue for both companies.